Aurigene to Present Multiple Programs at the AACR 2018 In Chicago, Illinois: (A) Novel Small Molecule, Oral, Antagonists of CD47-SIRPα Interaction; (B) Novel PRMT5 Inhibitors; (C) Covalent, Selective CDK12 Inhibitors and (D) SMARCA2/4 Degraders

Aurigene logo

Bangalore, India, April 11, 2018 / B3C newswire / -- Aurigene will present data for its

  1. Proprietary novel, first-in-class, small molecule antagonists of CD47-SIRPα interaction program which is currently in late preclinical stage. Aurigene plans to file an IND by Q4 2018
  2. Preclinical stage, novel, selective PRMT5 inhibitors
  3. Lead optimization stage covalent, highly selective CDK12 inhibitors program and
  4. Selective, degrader of SMARCA2/4

Additional information on the presentations can be found below and abstracts can be accessed at www.aacr.org.

Additional details of our pipeline available for partnering can be found at: http://www.aurigene.com/proprietary-programs/ 


Poster Presentations

Small Molecule, Oral antagonists targeting CD47- SIRPα
Title: Combination efficacy and safety profile of an orally bioavailable small molecule agent targeting CD47/SIRPα axis

Session Category: Experimental and Molecular Therapeutics
Session Title: Novel and Canonical Targets
Session Date and Time: Tuesday Apr 17, 2018 8:00 AM - 12:00 PM
Location:
McCormick Place South, Exhibit Hall A, Poster Section 35
Poster Board Number: 18
Permanent Abstract Number: 3852  


Covalent, selective, CDK12 inhibitors
Title: Preclinical evaluation of PD and efficacy of novel potent selective and orally bioavailable CDK12 covalent inhibitors in TNBC model

Session Category: Molecular and Cellular Biology / Genetics
Session Title: Kinases and Phosphatases
Session Date and Time: Monday Apr 16, 2018 1:00 PM - 5:00 PM
Location:
 McCormick Place South, Exhibit Hall A, Poster Section 17
Poster Board Number: 21
Permanent Abstract Number: 2384  


Selective PRMT5 inhibitors
Title: Preclinical In vivo evaluation of efficacy, pharmacokinetics and pharmacodynamics of novel PRMT5 inhibitors in multiple tumor models

Session Category: Molecular and Cellular Biology / Genetics
Session Title: Epigenetic Therapy
Session Date and Time: Monday Apr 16, 2018 8:00 AM - 12:00 PM
Location:
 McCormick Place South, Exhibit Hall A, Poster Section 16
Poster Board Number: 16
Permanent Abstract Number: 1392 


SMARCA2/4 degraders
Title: Identification of SMARCA2/4 degraders for the treatment of SMARCA4-mutant and other cancers

Session Title: Late-Breaking Research: Experimental and Molecular Therapeutics 3
Session Date and Time: Tuesday Apr 17, 2018 1:00 PM - 5:00 PM
Session Location:
McCormick Place South, Poster Section 43
Poster Board Number: 2
Permanent Abstract Number: LB-258        

 
About Aurigene
Aurigene is a specialized biotechnology company, engaged in discovery and clinical development of novel and best-in-class therapies to treat cancer and inflammatory diseases. Aurigene is focused on oral check-point inhibitors, precision-oncology and the Th-17 pathway.  Aurigene’s oral PD-L1/ VISTA antagonist program is currently in Phase 2 clinical development in India (trial initiated by Aurigene). Aurigene has filed an IND for its RORg program for autoimmune diseases and expects to initiate Phase I studies by Jun-2018. Aurigene has also developed selective CDK7 inhibitors with a likely IND by Q4 2018. Aurigene has partnered with several large- and mid-pharma companies in the United States and Europe and has delivered over 15 compounds which are in clinical development.

 
Contact

Rajshree KT
Director Strategic Alliances
This email address is being protected from spambots. You need JavaScript enabled to view it.
+91 - 40 - 4465 7777

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.